FlandersBio on Twitter

Follow us on Twitter

Archive for November 2015 - News

Archive for November 2015 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.



• Clinical Immunologist with more than 15 years combined FDA and pharmaceutical industry experience • Successfully developed a broad range of drugs in a number of important therapeutic indications read more

Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects


Walloon Government to fund further research into the preservation, properties and mechanism-of-action of Bone Therapeutics’ bone-forming cells. read more



Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody® drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody programme. read more

VIB starts up a research group on multiple sclerosis at UHasselt


The VIB/UHasselt Kleinewietfeld Lab was officially opened this morning. This research group is led by Prof. Markus Kleinewietfeld. Kleinewietfeld was appointed through an international selection process to further expand on his MS research at VIB (the Flanders Institute for Biotechnology) and the Hasselt University, where he is also active as a professor. The lab is located in the Biomedical Research Institute (BIOMED) at UHasselt and it is the first VIB group within this university. read more

Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015


Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to invite the Shareholders, Warrant Holders, Directors and Statutory Auditor of the Company to a Special Shareholders' Meeting that will be held on Tuesday 22 December 2015 at 2:00 p.m. (CET) at the registered office of the Company. read more

Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier


Galapagos NV (Euronext & NASDAQ: GLPG) announced today that GLPG1972, a first-in-class candidate drug aiming at treating osteoarthritis, has been dosed in a Phase 1 First-in-Human study. GLPG1972 has a novel mode of action discovered by Galapagos under its collaboration agreement with Servier, and has potential application in osteoarthritis. Galapagos will receive a €3.5 million milestone payment from Servier for this achievement. read more

VIB research presents new insights in the search for treatments for neurological diseases


A team of researchers led by professor Patrik Verstreken (VIB/KU Leuven) has exposed the fine details of a mechanism that provides more insight in the communication between neurons. The research has clarified how damaged synapses – the connection points between neurons – are repaired to keep communication between neurons at an optimal level. Disturbances in these mechanisms are believed to play a role in the development of neurodegenerative diseases, such as dementia, ALS or Parkinson’s disease. The results have been published in leading neuroscience journal ‘Neuron’. read more

ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole


ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today provides an overview of the presentations on JETREA®, which focused on the analysis of the OASIS study data, from the American Academy of Ophthalmology (AAO) 2015 meeting, held in Las Vegas from 14-17 November. read more

Celyad announces third quarter 2015 business update


Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today provided an update on key clinical and operational initiatives for the three-month period ended 30 September 2015. read more

TiGenix completes enrolment of its Phase I/II study in acute myocardial infarction


TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has completed enrolment of its Phase II study in acute myocardial Infarction (CAREMI study). read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top